Current financial headlines
Sharemaestro Newsreel
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
- Showing
- 145–180
- Headlines
- 195
- Sources here
- 13
- Companies here
- 9
Current section
Argentina Drug Manufacturers - General news
Chronological news
Earlier headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Earnings Scoreboard: 86% of S&P 500 reporting firms top EPS estimates as 79% post Y/Y profit growth
[Rolled newspaper with the headline Quarterly Results] Zerbor S&P 500 earnings activity accelerated this week, with more than 130 index members reporting quarterly results that provided key insights into corporate margin health, spending trends, and overall macroeconomic strength. EARNINGS ROUNDUP: * BOTTOM LINE (EPS): …
PFE
mentioned
Sharemaestro market context
Price above Trend Line
52 weeks +28.5%
Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed
In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside …
PFE
mentioned
Sharemaestro market context
Price above Trend Line
52 weeks +28.5%
The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?
Quick Read A blended portfolio made up of two-thirds dividend growth at 3.5% and one-third income at 6% generates $56,000 annually from $1.25M, beating the 4% rule without touching principal. Dividend growers like JNJ and AMGN raising payouts at 6% annually double retirement income …
JNJ
mentioned
Sharemaestro market context
Trend signal active
52 weeks +78.7% · Next-week setup positive 58.1%
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem
Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from …
LLY
main company
Sharemaestro market context
Trend signal active
52 weeks +109.5%
AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed
In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …
ABBV
main company
Sharemaestro market context
Trend signal active
52 weeks +44.9% · Next-week setup negative 42.7%
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound
Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been …
PFE
main company
Sharemaestro market context
Price above Trend Line
52 weeks +28.5%
Roche Stock Jumps as Morgan Stanley Sees Drug Breakout
This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. …
AZN
mentioned
Sharemaestro market context
Price below Trend Line
52 weeks +24.4%
Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …
Sharemaestro market context Trend signal active 52 weeks +78.7% · Next-week setup positive 58.1%NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
Novavax NVAX incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven …
PFE
mentioned
Sharemaestro market context
Price above Trend Line
52 weeks +28.5%
Johnson & Johnson presenta sólidos resultados del segundo trimestre, los ingresos y beneficios superan las expectativas y eleva sus previsiones, las acciones en el pre-market caen a contracorriente
JNJ
main company
Sharemaestro market context
Trend signal active
52 weeks +78.7% · Next-week setup positive 58.1%